z-logo
open-access-imgOpen Access
MicroRNA-373-3p inhibits the growth of cervical cancer by targeting AKT1 both in vitro and in vivo
Author(s) -
Minmin Yu,
Gen-ju Wang,
K. Wu,
Songlin Xue,
Li Ju,
Qian-rui Li,
Aiwei Xiong,
Guo-Ping Yin
Publication year - 2021
Publication title -
acta biochimica polonica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.452
H-Index - 78
eISSN - 1734-154X
pISSN - 0001-527X
DOI - 10.18388/abp.2020_5446
Subject(s) - akt1 , transfection , microrna , cell growth , cancer research , in vivo , western blot , cell culture , cervical cancer , microbiology and biotechnology , cancer , nude mouse , hela , cell , chemistry , biology , medicine , signal transduction , gene , biochemistry , genetics , pi3k/akt/mtor pathway
Objective: In this study, we aimed to investigate the function of microRNA-373-3p (miR-373-3p) in the pathogenesis of cervical cancer. Methods: Human and mouse cervical cancer cell lines were transfected with miR-373-3p mimic and inhibitor. Cell proliferation and viability were evaluated with Cell Counting Kit-8 (CCK-8) assay and Lactate Dehydrogenase (LDH) assay, respectively. The AKT1-targeting role of miR-373-3p was analyzed by qPCR and Western blot. Finally, a mouse xenograft cervical tumor model was adopted to study the in vivo effect of miR-373-3p on tumor growth and the expression of AKT1. Results: Over-expression of miR-373-3p significantly reduced the proliferation of cervical carcinoma cell line in vitro. In addition, miR-373-3p overexpression also inhibited cervical cancer growth in tumor-bearing mice. Mechanistically, we found that AKT1 gene can be targeted by miR-373-3p. MiR-373-3p mimic decreased the mRNA and protein expression of AKT1, while the miR-373-3p inhibitor increased the level of AKT1 in cervical cancer cells. AKT1 overexpression rescued the proliferation of cervical cancer cells transfected with miR-373-3p. Conclusion: MiR-373-3p can serve as a novel anti-tumor microRNA in cervical cancer by targeting AKT1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here